Each tablet contains 1.38mg Ketotifen Fumarate, which is equivalent to 1mg Ketotifen Base.
ZADITOFIN has the properties of antihistamines in addition to activities on mast cells analogous to those of sodium cromoglycate but it has no bronchodilator effect.
- In the prevention of bronchial asthma, it may take several weeks of treatment to achieve the full therapeutic effect. Therefore the product is not effective in acute attacks of asthma.
Adults: one tablet twice daily (in the morning and evening).
Otherwise as instructed by the physician.
Patients known to be easily sedated should begin treatment with the evening dose for the first few days.
Sedation, dry mouth, slight dizziness, and gastrointestinal disturbances may occur at the beginning of treatment, but usually disappear spontaneously with continued medication.
Occasionally, drowsiness has been observed, weight gain has also been reported.
Hypersensitivity to ketotifen or any of the excipients.
ZADITOFIN may potentiate the effect of CNS depressants and antihistamines.
A reversible fall in the thrombocyte count in patients receiving ketotifen concomitantly with oral antidiabetic agents has been observed in rare cases. Therefore it is not preferable with antidiabetics.
Care should be taken when driving machinery. Drug withdrawal should be gradually done.
USE IN PREGNANCY OR LACTATION:
The product like all drugs should be given to pregnant or nursing women only under compelling circumstances.
ABSORPTION AND ELIMINATION:
ZADITOFIN is absorbed from the gastrointestinal tract and together with its metabolites.
It is excerated in the urine and faeces.